INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 420m ago
HOUSE PTR20m ago
SEC 13F20m ago
ROBINHOOD CHAIN19m ago
Corporate insider
SR

Savitz Ryan

CFO & CBOCIK 0001992324

EDGAR filingsOpen in network
Disclosed transactions19
Buys / sells0 / 10
Max Insider Score27
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
16
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$739K
8,224 sh
Apr 9, 2026Apr 10, 2026
traded Apr 9, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Dianthus Therapeutics, Inc. /DE/CFO & CBO · Dec 5, 2025
0
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M
$147K
8,224 sh
Apr 9, 2026
Apr 10, 2026
traded Apr 9, 2026
+1d
SEC FORM 4

Evidence

0
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
8,224 sh
Apr 9, 2026Apr 10, 2026
traded Apr 9, 2026
+1dSEC FORM 4

Evidence

13
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$715K
40.0K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

9
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$109K
1,390 sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

19
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$1.72M
21.8K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

9
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$119K
1,485 sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

9
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$65K
800 sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

9
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$196K
2,366 sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

27
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$5.02M
59.8K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

27
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$1.65M
19.5K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

0
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
74.4K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

24
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$619K
7,232 sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

1
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$628K
74.4K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

7
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
40.0K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

5
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Grant or award
A—
150.0K sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC FORM 4

Evidence

7
SR
Savitz RyanCFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
20.0K sh
Dec 4, 2025Dec 5, 2025
traded Dec 4, 2025
+1dSEC FORM 4

Evidence

23
SR
Savitz RyanCFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$904K
20.0K sh
Dec 4, 2025Dec 5, 2025
traded Dec 4, 2025
+1dSEC FORM 4

Evidence

2
SR
Savitz RyanCFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$169K
20.0K sh
Dec 4, 2025Dec 5, 2025
traded Dec 4, 2025
+1dSEC FORM 4

Evidence